Cancer Biology and Therapeutics (CBT)

项目摘要/摘要：癌症生物学与治疗学 癌症生物学和治疗(CBT)计划汇集了37名教职员工，代表12个系 在达特茅斯的盖泽尔医学院(Geisel)，其瓜里尼研究生和高级研究学院，以及 达特茅斯-希区柯克医学中心(DH)，其研究兴趣与三个中央CBT计划相关 主题：1)癌细胞信号与代谢，2)细胞周期生物学与基因组稳定性，3)染色质 生物学和致癌基因转录。CBT计划的共同目标是：i)推动 了解癌症发生、发展和转移的基本机制，以支持 癌症的预防、诊断和治疗；二)确定和验证新的途径和分子靶点 有效的治疗干预；iii)促进双向翻译，发展和改进小说 治疗和诊断策略。目前由同行评审的癌症相关研究直接成本支持 总计700万美元，其中NCI资金占25%(180万美元)，总直接成本为790万美元。二十(20) CBT计划成员目前共有28个CCSG定义的R01等值奖项。使用相同的 2014年与癌症有关的直接费用的定义(即不包括所有间接费用以及培训和 行政直接成本)、同行评议的癌症相关研究直接成本(700万美元)相比上涨了14% 2014年用于癌症机制和分子治疗相结合(610万美元)。自2015年以来，CBT 该方案有446份与癌症有关的出版物，22%(98份)是方案内出版物，24%(109份)是方案间出版物， 52%(232)来自其他机构的研究人员，24%(97)在高影响力期刊(即影响因子)中 &gt；8)。与2014年癌症机制和分子治疗相结合相比，INTERNAL 方案出版物增加，从15%增加到22%，方案间出版物增加(从 21%)和高影响(从22%增加到24%)。CBT计划将继续 通过建立和加强两国之间的多学科合作来实现拟议的具体目标 基础、翻译和临床研究人员，初级教员对学术独立的指导， 以及促进临床医生和实验室科学家之间的伙伴关系，以推动研究人员的发展- 启动了临床研究。

Project Summary/Abstract: Cancer Biology and Therapeutics The Cancer Biology and Therapeutics (CBT) Program brings together 37 faculty, representing 12 departments at Dartmouth’s Geisel School of Medicine (Geisel), its Guarini School of Graduate and Advanced Studies, and the Dartmouth-Hitchcock Medical Center (DH), with research interests relevant to three central CBT Program themes: 1) Cancer cell signaling and metabolism, 2) Cell cycle biology and genome stability, and 3) Chromatin biology and oncogenic transcription. The shared goals of the CBT Program are to: i) advance the understanding of the basic mechanisms that underlie cancer initiation, progression, and metastasis to support prevention, diagnosis and treatment of cancer; ii) identify and validate new pathways and molecular targets for effective therapeutic intervention; iii) facilitate bi-directional translation to develop and improve novel therapeutic and diagnostic strategies. Peer-reviewed cancer-related research direct cost support currently totals $7.0M, with NCI funding representing 25% ($1.8M) and total direct costs summing to $7.9M. Twenty (20) CBT Program Members currently have a total of 28 CCSG-defined R01-equivalent awards. Using the same definition of cancer-related direct costs in 2014 (i.e., excluding all indirects as well as training and administrative direct costs), peer-reviewed cancer-related research direct costs ($7.0M) are up 14% compared to the combination of Cancer Mechanisms and Molecular Therapeutics in 2014 ($6.1M). Since 2015, the CBT Program has 446 cancer-related publications, 22% (98) intra-programmatic, 24% (109) inter-programmatic, 52% (232) with investigators from other institutions, and 24% (97) in high impact journals (i.e., impact factor >8). Compared to the combination of Cancer Mechanisms and Molecular Therapeutics in 2014, intra- programmatic publications have increased, to 22% from 15%, along with inter-programmatic (to 24% from 21%) and high impact (to 24% from 22%) in the current reporting period. The CBT Program will continue to pursue the proposed Specific Aims through building and strengthening multidisciplinary collaborations between basic, translational, and clinical researchers, mentorship of junior faculty members to academic independence, and promotion of partnerships of clinicians and laboratory scientists to drive the development of investigator- initiated clinical studies.